Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 6, 2013, Pages 1599-1607

  Sonnichsen, Daryl ^a,b   Dorer, David J ^a   Cortes, Jorge ^c   Talpaz, Moshe ^d   Deininger, Michael W ^e,i   Shah, Neil P ^f   Kantarjian, Hagop M ^c   Bixby, Dale ^d   Mauro, Michael J ^e   Flinn, Ian W ^g   Litwin, Jeffrey ^h   Turner, Christopher D ^a   Haluska, Frank G ^a  

^a ARIAD PHARMACEUTICALS INC   (United States)

^b Sonnichsen Pharmaceutical Associates   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SARAH CANNON RESEARCH INSTITUTE   (United States)

^h ERT   (United States)

ⁱ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

BCR ABL; Chronic myeloid leukemia; Drug safety; Electrocardiography; Philadelphia chromosome; Ponatinib

Indexed keywords

DEXTROPROPOXYPHENE; PONATINIB;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPLETE HEART BLOCK; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART BUNDLE BRANCH BLOCK; HEART INFARCTION; HEART REPOLARIZATION; HEMATOLOGIC MALIGNANCY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RECOMMENDED DRUG DOSE; SECOND DEGREE ATRIOVENTRICULAR BLOCK; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; T WAVE INVERSION;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HEART; HEMATOLOGIC NEOPLASMS; HUMANS; IMIDAZOLES; LONG QT SYNDROME; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; PYRIDAZINES;

EID: 84878666154     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2160-7     Document Type: Article

References (22)

1. Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y, Zou D, Thomas RM, Zhu X, Cai L, Wen D, Liu S, Romero J, Qi J, Chen I, Banda G, Lentini SP, Das S, Xu Q, Keats J, Wang F, Wardwell S, Ning Y, Snodgrass JT, Broudy MI, Russian K, Zhou T, Commodore L, Narasimhan NI, Mohemmad QK, Iuliucci J, Rivera VM, Dalgarno DC, Sawyer TK, Clackson T, Shakespeare WC (2010) Discovery of 3-[2-(imidazo[1,2-b] pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 53:4701-4719
2. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401-412
3. Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J, Xu Q, Rivera VM, Shakespeare WC, Clackson T, Dalgarno DC, Zhu X (2011) Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77:1-11
4. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M (2012) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367:2075-2088. doi: 10.1056/NEJMoa1205127
5. Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah N, Kantarjian HM, The PACE Study Group (2012) A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. Blood 120: Abstract 163
6. ARIAD Pharmaceuticals Inc. Iclusig (ponatinib) tablets prescribing information (2012) http://iclusig.com/wp-content/uploads/2012/12/Iclusig- Prescribing-Information.pdf. Accessed 18 Dec 2012
7. Novartis (2013) Gleevec (imatinib mesylate) prescribing information. www.pharma.us.novartis.com/product/pi/pdf/gleevec-tabs.pdf. Accessed 30 Aug 2012
8. Novartis (2012) Tasigna (nilotinib) prescribing information. www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf. Accessed 30 Aug 2012
9. Bristol-Myers Squibb (2012) Sprycel (dasatinib) prescribing information. http://packageinserts.bms.com/pi/pi-sprycel.pdf. Accessed 30 Aug 2012
10. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (2005) ICH harmonised tripartite guidelines. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: E14. www.ich.org/ fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-Guideline. pdf. Accessed 30 Aug 2012
11. Wisialowski T, Crimin K, Engtrakul J, O'Donnell J, Fermini B, Fossa AA (2006) Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. J Pharmacol Exp Ther 318:352-359
12. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908-916. doi: 10.1038/nm1446
13. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, for the Iris Investigators, (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417. doi: 10.1056/NEJMoa062867
14. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, for the Iris Investigators, (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004. doi: 10.1056/NEJMoa022457
15. Bristol-Myers Squibb sprycel clinical pharmacology review (2012) www.accessdata.fda.gov/drugsatfda-docs/nda/2006/021986s000-Sprycel--ClinPharmR. pdf. Accessed 30 Aug 2012
16. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boque C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270. doi: 10.1056/NEJMoa1002315
17. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551. doi: 10.1056/NEJMoa055104
18. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD (2011) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117:1141-1145. doi: 10.1182/blood-2010-03-277152
19. Novartis Tasigna clinical pharmacology review (2007) http://www. accessdata.fda.gov/drugsatfda-docs/nda/2007/022068s000-ClinPharmR.pdf. Accessed 30 Aug 2012
20. Kantarjian H, Flinn IW, Goldberg S, Bunworasate U, Zanichelli MA, Nakamae H, Hughes TP, Hochhaus A, Saglio G, Woodman RC, Blakesley RE, Kemp CN, Kalaycio ME, Larson RA (2012) Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u). J Clin Oncol 30(suppl):Abstract 6509
21. Larson RA, Hochhaus A, Saglio G, Rosti G, Lopez JL, Stenke L, Nakamae H, Goldberg SL, Wang M, Gallagher NJ, Hoenekopp A, Ortmann C, Hughes TP, Kantarjian HM (2010) Cardiac safety profile of imatinib and nilotinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): results from ENESTnd. Blood 116:Abstract 2291
22. Abbas R, Hug BA, Leister C, Sonnichsen D (2012) A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects. Int J Cancer 131:E304-E311. doi: 10.1002/ijc.27348